---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-005859"
form_type: "8-K"
ticker: "CVKD"
cik: "0001937993"
company_name: "Cadrenal Therapeutics, Inc."
filed_at: "2023-10-23T23:59:59+00:00"
generated_at: "2026-06-09T17:23:26.827911+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Cadrenal Therapeutics stockholders elect directors and ratify auditor at 2023 annual meeting

## Summary
- Quang Pham re-elected as Class I director with 10,183,242 votes for, 8,560 withheld; Glynn Wilson with 10,139,612 for, 52,190 withheld.
- WithumSmith+Brown, P.C. ratified as independent auditor for fiscal 2023 with 11,126,433 for, 10,899 against, 192 abstain.
- Quorum achieved with over 34% of 13,022,754 outstanding shares represented at the October 20, 2023 meeting.
- Broker non-votes totaled 945,722 for each director election; none for the auditor ratification (routine matter).

## SEC filing metadata
- accession: 0001013762-23-005859
- form_type: 8-K
- ticker: CVKD
- cik: 0001937993
- company_name: Cadrenal Therapeutics, Inc.
- filed_at: 2023-10-23T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937993/000101376223005859/0001013762-23-005859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937993/000101376223005859/ea187126-8k_cadrenal.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-005859
- JSON: https://secwatch.observer/filing/0001013762-23-005859.json
- Plain text: https://secwatch.observer/filing/0001013762-23-005859.txt

## Key facts
- Shareholder Votes
  Cadrenal Therapeutics, Inc. shareholders approved Ratification of the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-10-20 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-10-20
  source text: Proposal 2 . Ratification of the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 . The stockholders ratified and approved the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 based on the votes listed below: Votes For Votes Against Abstentions Broker Non-Votes 11,126,433 10,899 192 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000101376223005859/0001013762-23-005859-index.htm
- Shareholder Votes
  Cadrenal Therapeutics, Inc. shareholders approved Election of Directors at the 2023-10-20 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-10-20
  source text: Proposal 1 . Election of Directors . The following two (2) individuals were elected as Class I directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified with the following votes: Name of Director Votes For Withheld Broker Non-Votes Quang Pham 10,183,242 8,560 945,722 Glynn Wilson 10,139,612 52,190 945,722
  evidence_url: https://www.sec.gov/Archives/edgar/data/1937993/000101376223005859/0001013762-23-005859-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.